News
The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors and fulvestrant, a SERD, in preclinical in-vitro breast cancer models
Deepak Lala, Tasir Haque, Hannah Feinman, Jianghong Wu, Yuren Wang, Amy Dwyer, Thu Truong, and Carol Lange
San Antonio Breast Cancer Symposium I Poster P6-20-13 I Dec 4-8, 2018
Context Announces Presentation of New Preclinical Data on Apristor in Combination with a Cdk4/6 Inhibitor at San Antonio Breast Cancer Symposium
Context Therapeutics, a clinical-stage biotechnology company, today announced that new preclinical data on Apristor®, its first-in-class full progesterone receptor antagonist, will be featured at the San Antonio Breast Cancer Symposium® taking place on December 4-8, 2018 in San Antonio, TX.
Context Reports Encouraging Phase 1 Safety and Efficacy Data of Apristor®
PHILADELPHIA--(BUSINESS WIRE)—October 11, 2018—Context Therapeutics today announced Phase 1 data for its investigational new drug, Apristor® (Onapristone extended release), an oral progesterone receptor antagonist that is being developed for progesterone receptor-positive (PR+) cancers.